Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Role of F-18 FDG PET or PET/CT in the Evaluation of Gastric Cancer

위암 평가에 있어 F-18 FDG PET 또는 PET/CT의 역할

  • Yun, Mi-Jin (Division of Nuclear Medicine, Department of Diagnostic Radiology Yonsei University College of Medicine)
  • 윤미진 (연세대학교 의과대학 핵의학과)
  • Published : 2006.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

PET detects only less than 50% of early gastric cancer and 62-98% of advanced gastric cancer. Therefore, mass screening programs are recommended for all adults over the age of 40 for early detection and early treatment of gastric cancer through endoscopy or various radiological tests. The most important step after being diagnosed with gastric cancer is accurate staging, which mainly evaluates tumor resectability to avoid unnecessary surgery. Important factors that affect tumor resectability are whether the tumor can be separated from adjacent organs or important blood vessels, the extent of lymph node metastasis, presence of peritoneal metastasis, or distant organ metastasis. To evaluate the extent of local tumor invasion, anatomical imaging that has superior spatial resolution is essential. There are a few studies on prognostic significance of FDG uptake with inconsistent results between them. In spite of lower sensitivities for lymph node staging, the specificities of CT and PET are very high, and the specificity for PET tends to be higher than that for CT. Limited data published so far show that PET seems less useful in the detection of lung and bone metastasis. In the evaluation of pleural or peritoneal metastasis, PET seems very specific but insensitive as well. When FDG uptake of the primary tumor is low, the distant metastasis is also known to show low FDG uptake reducing its detection. There are only a few data available in the evaluation of recurrence detection and treatment response using FDG PET.

Keywords

References

  1. Abe S, Yoshimura H, Nagaoka S, Monden N, Kinugasa S, Nagasue N, et al. Long-term results of operation for carcinoma of the stomach in T1/T2 stages: critical evaluation of the concept of early carcinoma of the stomach. J Am Coll Surg 1995;181:389-96
  2. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-55 https://doi.org/10.1053/ctrv.2000.0164
  3. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14 Suppl 2:ii31-6
  4. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of ^{18}F$-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-9
  5. Yun M, Lim J, Noh S, Hyung WJ, Cheong JH, Bong JK, et al. Lymph Node Staging of Gastric Cancer Using FDG PET; A Comparison Study with CT. J Nucl Med 2005;46:1582-8
  6. Yun M, Kim HK, Kim HR, Kim TS, Cho A, Lee JD. Histopathologic features of adenocarcinomas of the stomach affecting FDG uptake on PET. J Nucl Med (Abstract). 2006; 466P
  7. Lee HJ, Yun M, Ko D, Ryu YH, Lee JD. Use of hydro-FDG PET in the detection of primary tumors of the stomach. J Nucl Med (Abstract). 2005;424P
  8. Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on $^{18}F$-FDG PET. J Nucl Med 2005;46:953-7
  9. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-9 https://doi.org/10.1007/s00259-001-0743-8
  10. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-95 https://doi.org/10.1007/s00259-002-1029-5
  11. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-25 https://doi.org/10.1007/BF01655804
  12. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-90 https://doi.org/10.1002/cncr.21074
  13. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using $^{18}F$-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-55 https://doi.org/10.1007/s00259-005-1887-8
  14. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of $^{18}F$-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-53 https://doi.org/10.1007/s00268-003-7191-5
  15. Gryspeerdt S, Clabout L, Van Hoe L, Berteloot P, Vergote IB. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer. Eur J Gynaecol Oncol 1998;19:434-7
  16. Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513-20 https://doi.org/10.1148/radiology.204.2.9240546
  17. Tanaka T, Kawai Y, Kanai M, Taki Y, Nakamoto Y, Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg 2002;184: 433-6 https://doi.org/10.1016/S0002-9610(02)01004-8
  18. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of $^{18}F$-FDG PET. J Nucl Med 2003;44:1407-12
  19. Ko D, Yun M, Lim J, Noh S, Ryu Y, Lee JD. Detection of peritoneal carcinomatosis in patients with gastric adenocarcinoma: Is PET more accurate than CT. J Nucl Med (Abstract) 2005;425P
  20. Lim J, Yun M, Kim M, Hyung WJ, Park MS, Choi JY, et al. The role of CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006;26:143-56 https://doi.org/10.1148/rg.261055078
  21. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-56 https://doi.org/10.1148/radiol.2243011362
  22. Buyyounouski MK, Klump WJ, Konski A, Wu H, Adler LP. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. Clin Nucl Med 2005;30:118-9 https://doi.org/10.1097/00003072-200502000-00014
  23. Tian J, Chen L, Wei B, Shao M, Ding Y, Yin D, et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. Nucl Med Commun 2004;25:825-31 https://doi.org/10.1097/01.mnm.0000135042.54461.f6
  24. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003;58:215-21 https://doi.org/10.1016/S0009-9260(02)00477-4
  25. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42 https://doi.org/10.1046/j.1365-2168.2000.01360.x
  26. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-10
  27. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004;31:1471-78 https://doi.org/10.1007/s00259-004-1626-6